Ascletis' ASC47 shows stronger efficacy with tirzepatide

Ascletis Pharma announced preclinical results for ASC47, a muscle-preserving weight loss drug candidate. In obese mice, low-dose ASC47 combined with tirzepatide achieved 87% greater body weight reduction versus tirzepatide alone, and 55% greater reduction compared to ASC47 with semaglutide.

The combination also restored muscle mass percentage to levels similar to healthy mice.